Selegiline transdermal system

Current awareness and promise

Chi Un Pae, Hyun Kook Lim, Changsu Han, Ajwani Neena, Chul Lee, Ashwin A. Patkar

Research output: Contribution to journalReview article

26 Citations (Scopus)

Abstract

Many monoamine oxidase inhibitors (MAOIs) have been used to treat major depressive disorder (MDD). However, the prescription of MAOIs has decreased considerably as a result of side effects such as tyramine-induced hypertensive crisis, which is also known as the 'Cheese Effect'. The drug delivery system itself can affect the bioavailability of certain drugs, which might influence the efficacy and tolerability of medications, as well as improve the compliance and reduce the incidence of recurrence and relapse. Therefore, there is a need for advanced drug delivery techniques that can evade the potentially hazardous toxic effects of the parent compound, including extended-release oral, cutaneous, intravesical and intravaginal routes, etc. In this context, the selegiline transdermal system (STS, EMSAM™) was introduced with improved side effect profiles and efficacy compared with the conventional form of the selegiline oral tablet. STS allows the targeted inhibition of the monoamine A (MAO-A) and MAO-B isoenzymes with minimal effects on the MAO-A in the gastrointestinal and hepatic systems. Hence, STS can reduce the risk of interactions with tyramine-rich foods. Many fundamental clinical and preclinical studies have reported that 6 mg/24 h of STS is effective against MDD without the need for dietary restrictions with an equal efficacy and improved safety profile. In addition, STS might benefit MDD patients with atypical features or who are resistant to other antidepressants. Overall, familiarity with the properties and indications of STS will have the clinicians another option of biological treatments for MDD patients but subsequent more data including actual post-market clinical experiences will be mandatory.

Original languageEnglish
Pages (from-to)1153-1163
Number of pages11
JournalProgress in Neuro-Psychopharmacology and Biological Psychiatry
Volume31
Issue number6
DOIs
Publication statusPublished - 2007 Aug 15

Fingerprint

Selegiline
Major Depressive Disorder
Monoamine Oxidase
Tyramine
Monoamine Oxidase Inhibitors
Recurrence
Poisons
Cheese
Drug Delivery Systems
Pharmaceutical Preparations
Antidepressive Agents
Biological Availability
Isoenzymes
Tablets
Compliance
Prescriptions
Safety
Food
Skin
Liver

Keywords

  • Depression
  • Drug delivery system
  • Efficacy and tolerability
  • Monoamine oxidase inhibitor
  • Selegiline
  • Selegiline transdermal system (STS, EMSAM™)

ASJC Scopus subject areas

  • Pharmacology
  • Biological Psychiatry

Cite this

Selegiline transdermal system : Current awareness and promise. / Pae, Chi Un; Lim, Hyun Kook; Han, Changsu; Neena, Ajwani; Lee, Chul; Patkar, Ashwin A.

In: Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 31, No. 6, 15.08.2007, p. 1153-1163.

Research output: Contribution to journalReview article

Pae, Chi Un ; Lim, Hyun Kook ; Han, Changsu ; Neena, Ajwani ; Lee, Chul ; Patkar, Ashwin A. / Selegiline transdermal system : Current awareness and promise. In: Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2007 ; Vol. 31, No. 6. pp. 1153-1163.
@article{f0cf30cc56c640569b0a38ae50bd8553,
title = "Selegiline transdermal system: Current awareness and promise",
abstract = "Many monoamine oxidase inhibitors (MAOIs) have been used to treat major depressive disorder (MDD). However, the prescription of MAOIs has decreased considerably as a result of side effects such as tyramine-induced hypertensive crisis, which is also known as the 'Cheese Effect'. The drug delivery system itself can affect the bioavailability of certain drugs, which might influence the efficacy and tolerability of medications, as well as improve the compliance and reduce the incidence of recurrence and relapse. Therefore, there is a need for advanced drug delivery techniques that can evade the potentially hazardous toxic effects of the parent compound, including extended-release oral, cutaneous, intravesical and intravaginal routes, etc. In this context, the selegiline transdermal system (STS, EMSAM™) was introduced with improved side effect profiles and efficacy compared with the conventional form of the selegiline oral tablet. STS allows the targeted inhibition of the monoamine A (MAO-A) and MAO-B isoenzymes with minimal effects on the MAO-A in the gastrointestinal and hepatic systems. Hence, STS can reduce the risk of interactions with tyramine-rich foods. Many fundamental clinical and preclinical studies have reported that 6 mg/24 h of STS is effective against MDD without the need for dietary restrictions with an equal efficacy and improved safety profile. In addition, STS might benefit MDD patients with atypical features or who are resistant to other antidepressants. Overall, familiarity with the properties and indications of STS will have the clinicians another option of biological treatments for MDD patients but subsequent more data including actual post-market clinical experiences will be mandatory.",
keywords = "Depression, Drug delivery system, Efficacy and tolerability, Monoamine oxidase inhibitor, Selegiline, Selegiline transdermal system (STS, EMSAM™)",
author = "Pae, {Chi Un} and Lim, {Hyun Kook} and Changsu Han and Ajwani Neena and Chul Lee and Patkar, {Ashwin A.}",
year = "2007",
month = "8",
day = "15",
doi = "10.1016/j.pnpbp.2007.04.020",
language = "English",
volume = "31",
pages = "1153--1163",
journal = "Progress in Neuro-Psychopharmacology and Biological Psychiatry",
issn = "0278-5846",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Selegiline transdermal system

T2 - Current awareness and promise

AU - Pae, Chi Un

AU - Lim, Hyun Kook

AU - Han, Changsu

AU - Neena, Ajwani

AU - Lee, Chul

AU - Patkar, Ashwin A.

PY - 2007/8/15

Y1 - 2007/8/15

N2 - Many monoamine oxidase inhibitors (MAOIs) have been used to treat major depressive disorder (MDD). However, the prescription of MAOIs has decreased considerably as a result of side effects such as tyramine-induced hypertensive crisis, which is also known as the 'Cheese Effect'. The drug delivery system itself can affect the bioavailability of certain drugs, which might influence the efficacy and tolerability of medications, as well as improve the compliance and reduce the incidence of recurrence and relapse. Therefore, there is a need for advanced drug delivery techniques that can evade the potentially hazardous toxic effects of the parent compound, including extended-release oral, cutaneous, intravesical and intravaginal routes, etc. In this context, the selegiline transdermal system (STS, EMSAM™) was introduced with improved side effect profiles and efficacy compared with the conventional form of the selegiline oral tablet. STS allows the targeted inhibition of the monoamine A (MAO-A) and MAO-B isoenzymes with minimal effects on the MAO-A in the gastrointestinal and hepatic systems. Hence, STS can reduce the risk of interactions with tyramine-rich foods. Many fundamental clinical and preclinical studies have reported that 6 mg/24 h of STS is effective against MDD without the need for dietary restrictions with an equal efficacy and improved safety profile. In addition, STS might benefit MDD patients with atypical features or who are resistant to other antidepressants. Overall, familiarity with the properties and indications of STS will have the clinicians another option of biological treatments for MDD patients but subsequent more data including actual post-market clinical experiences will be mandatory.

AB - Many monoamine oxidase inhibitors (MAOIs) have been used to treat major depressive disorder (MDD). However, the prescription of MAOIs has decreased considerably as a result of side effects such as tyramine-induced hypertensive crisis, which is also known as the 'Cheese Effect'. The drug delivery system itself can affect the bioavailability of certain drugs, which might influence the efficacy and tolerability of medications, as well as improve the compliance and reduce the incidence of recurrence and relapse. Therefore, there is a need for advanced drug delivery techniques that can evade the potentially hazardous toxic effects of the parent compound, including extended-release oral, cutaneous, intravesical and intravaginal routes, etc. In this context, the selegiline transdermal system (STS, EMSAM™) was introduced with improved side effect profiles and efficacy compared with the conventional form of the selegiline oral tablet. STS allows the targeted inhibition of the monoamine A (MAO-A) and MAO-B isoenzymes with minimal effects on the MAO-A in the gastrointestinal and hepatic systems. Hence, STS can reduce the risk of interactions with tyramine-rich foods. Many fundamental clinical and preclinical studies have reported that 6 mg/24 h of STS is effective against MDD without the need for dietary restrictions with an equal efficacy and improved safety profile. In addition, STS might benefit MDD patients with atypical features or who are resistant to other antidepressants. Overall, familiarity with the properties and indications of STS will have the clinicians another option of biological treatments for MDD patients but subsequent more data including actual post-market clinical experiences will be mandatory.

KW - Depression

KW - Drug delivery system

KW - Efficacy and tolerability

KW - Monoamine oxidase inhibitor

KW - Selegiline

KW - Selegiline transdermal system (STS, EMSAM™)

UR - http://www.scopus.com/inward/record.url?scp=34447526443&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34447526443&partnerID=8YFLogxK

U2 - 10.1016/j.pnpbp.2007.04.020

DO - 10.1016/j.pnpbp.2007.04.020

M3 - Review article

VL - 31

SP - 1153

EP - 1163

JO - Progress in Neuro-Psychopharmacology and Biological Psychiatry

JF - Progress in Neuro-Psychopharmacology and Biological Psychiatry

SN - 0278-5846

IS - 6

ER -